Table 1.
Initiators characteristics at inclusion and during the study follow-up, by molecule and product type.
| Infliximab | Etanercept | Adalimumab | ||||
|---|---|---|---|---|---|---|
| Biosimilar | Originator | Biosimilar | Originator | Biosimilar | Originator | |
| Effective | 20,208 (78) | 5742 (22) | 12,713 (46) | 15,014 (54) | 26,033 (53) | 22,735 (47) |
| Female | 10,377 (51) | 3012 (52) | 7907 (62) | 9529 (63) | 14,379 (55) | 12,599 (55) |
| Age at inclusion (years) | – | – | – | – | – | – |
| Mean (SD) | 43.9 (16.3) | 43.9 (16.1) | 51.9 (15.2) | 50.7 (15.1) | 45.2 (15) | 43.6 (15.4) |
| 18–29 | 4666 (23) | 1315 (23) | 1004 (8) | 1298 (9) | 4576 (18) | 4862 (21) |
| 30–39 | 4285 (21) | 1188 (21) | 1992 (16) | 2531 (17) | 5555 (21) | 5063 (22) |
| 40–49 | 3920 (19) | 1185 (21) | 2466 (19) | 3311 (22) | 5632 (22) | 4828 (21) |
| 50–59 | 3464 (17) | 982 (17) | 3150 (25) | 3577 (24) | 5412 (21) | 4110 (18) |
| 60–69 | 2404 (12) | 671 (12) | 2328 (18) | 2531 (17) | 3231 (12) | 2516 (11) |
| 70 + | 1469 (7) | 401 (7) | 1773 (14) | 1766 (12) | 1627 (6) | 1356 (6) |
| Pathology | – | – | – | – | – | – |
| Gastro-enterology | – | – | – | – | – | – |
| Crohn's Disease | 7914 (39) | 2407 (42) | 0 (0) | 0 (0) | 5583 (21) | 7127 (31) |
| Ulcerative colitis | 4358 (22) | 1058 (18) | 0 (0) | 0 (0) | 2697 (10) | 4122 (18) |
| Rheumatology | – | – | – | – | – | – |
| Rheumatoid arthritis | 1607 (8) | 446 (8) | 5997 (47) | 5618 (37) | 3888 (15) | 1717 (8) |
| Ankylosing spondylitis | 3358 (17) | 781 (14) | 4441 (35) | 5356 (36) | 8449 (32) | 3811 (17) |
| Psoriatic arthritis | 448 (2) | 142 (2) | 688 (5) | 920 (6) | 1387 (5) | 664 (3) |
| Dermatology | – | – | – | – | – | – |
| Psoriasis | 862 (4) | 294 (5) | 573 (5) | 1320 (9) | 1926 (7) | 2013 (9) |
| Hidradenitis Suppurativa | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 52 (0) | 267 (1) |
| Ophtalmology | – | – | – | – | – | – |
| Uveitis | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 204 (1) | 538 (2) |
| Undetermined | 1661 (8) | 614 (11) | 1014 (8) | 1800 (12) | 1847 (7) | 2476 (11) |
| Follow-up duration, mean (SD) | 1.6 (1.5) | 2.4 (2.1) | 1.3 (1.1) | 1.7 (1.6) | 0.9 (0.7) | 1.1 (0.9) |
| Follow-up duration, median (IQR) | 1 (0.5–2.3) | 1.5 (0.6–4) | 0.8 (0.4–2) | 1 (0.4–2.8) | 0.7 (0.4–1.3) | 0.8 (0.4–1.8) |
| Number of dispensings, mean (SD) | 11.7 (10.9) | 16.4 (15.2) | 13.8 (12.8) | 17 (17.4) | 10.4 (8.5) | 12.5 (10.5) |
| Discontinuation, molecule switch or death | 10,070 (50) | 3830 (67) | 6228 (49) | 9763 (65) | 8967 (34) | 9338 (41) |
| Transitions | 816 (4) | 2031 (35) | 225 (2) | 1575 (10) | 370 (1) | 1396 (6) |
| Time to switch, median (IQR) | 0.9 (0.4–1.7) | 1.6 (0.6–2.6) | 0.9 (0.4–1.7) | 1.6 (0.7–2.5) | 0.5 (0.3–0.9) | 0.6 (0.2–1.1) |
| Retransitions | 1226 (6) | 439 (8) | 712 (6) | 528 (4) | 1634 (6) | 417 (2) |
| Time to switch, median (IQR) | 0.5 (0.2–1.2) | 2 (1–3.2) | 0.4 (0.2–0.9) | 2.2 (1.3–3.1) | 0.3 (0.1–0.6) | 0.8 (0.4–1.5) |
| Biotransitions | 2277 (11) | 300 (5) | 291 (2) | 47 (0) | 644 (2) | 71 (0) |
| Time to switch, median (IQR) | 1.2 (0.6–2.2) | 3.2 (2.4–4.6) | 0.5 (0.2–1.1) | 2.7 (1.4–3.5) | 0.4 (0.2–0.8) | 1.2 (0.7–1.7) |
Figures are no. (%) unless stated otherwise.
IQR, interquartile range; SD, standard deviation.